111 related articles for article (PubMed ID: 3217777)
21. Therapeutic dilemmas: balancing the risks of bleeding, thrombosis, and leukemic transformation in myeloproliferative disorders (MPD).
Murphy S
Thromb Haemost; 1997 Jul; 78(1):622-6. PubMed ID: 9198227
[TBL] [Abstract][Full Text] [Related]
22. Oral anticoagulants as secondary prophylaxis of thrombosis in patients with polycythemia vera: a retrospective analysis of 15 patients.
Bachleitner-Hofmann T; Grumbeck E; Gisslinger H
Thromb Res; 2003; 112(4):229-32. PubMed ID: 14987916
[TBL] [Abstract][Full Text] [Related]
23. [Radioactive phosphorus (32P); an old but not bad treatment for polycythemia vera].
Tesselaar ME; Wijermans PW; Metsaars JA; Gerrits WB; Haak HL
Ned Tijdschr Geneeskd; 1996 Sep; 140(38):1900-2. PubMed ID: 8927166
[TBL] [Abstract][Full Text] [Related]
24. Symptomatic venous thromboembolism in acute leukemia. Incidence, risk factors, and impact on prognosis.
Ziegler S; Sperr WR; Knöbl P; Lehr S; Weltermann A; Jäger U; Valent P; Lechner K
Thromb Res; 2005; 115(1-2):59-64. PubMed ID: 15567454
[TBL] [Abstract][Full Text] [Related]
25. [Treatment of polycythemia. I--Using radiophosphorus with or without treatment in 483 patients over 65 years of age].
Najean Y; Rain JD; Goguel A; Grange MJ; Vigneron N; Dupuy E; Mougeot-Martin M
Ann Med Interne (Paris); 1998 Mar; 149(2):87-93. PubMed ID: 11490530
[TBL] [Abstract][Full Text] [Related]
26. The use of 32 phosphorus (32P) in the treatment of polycythemia vera.
Parmentier C; Gardet P
Nouv Rev Fr Hematol (1978); 1994 Apr; 36(2):189-92. PubMed ID: 8036140
[TBL] [Abstract][Full Text] [Related]
27. Splenectomy after portal thrombosis in patients with polycythemia vera and essential thrombocythemia.
Randi ML; Fabris F; Ruzzon E; Pacquola E; Cella G; Girolami A
Haematologica; 2002 Nov; 87(11):1180-4. PubMed ID: 12414348
[TBL] [Abstract][Full Text] [Related]
28. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
29. Post-polycythemia myeloid metaplasia: experience with a large cohort of patients.
Randi ML; Barbone E; Fabris F; Varotto L; Macri C; Girolami A
J Med; 1994; 25(6):363-9. PubMed ID: 7769374
[TBL] [Abstract][Full Text] [Related]
30. [Polycythemias of young subjects (author's transl)].
Le Mercier N; Najean Y
Nouv Presse Med; 1979 Jan; 8(2):93-7. PubMed ID: 554080
[TBL] [Abstract][Full Text] [Related]
31. [Prevention of vascular complications in polycythemia vera and primary thrombocythemia treated with low doses of acetylsalicylic acid].
Fröhli P; Graf C; Rhyner K
Schweiz Med Wochenschr; 1983 Nov; 113(44):1622-7. PubMed ID: 6685916
[TBL] [Abstract][Full Text] [Related]
32. Course and transformation of polycythaemia vera in relation to therapy.
Burger T; Schmelczer M; Molnár L; Pajor L; Koszorus S
Acta Med Hung; 1988; 45(1):97-113. PubMed ID: 3412864
[TBL] [Abstract][Full Text] [Related]
33. [Treatment of polycythemia. II.--Comparison of hydroxyurea with pipobroman in 294 patients less than 65 years of age].
Najean Y; Rain JD; Lejeune F; Echard M; Fermand JP; Gruyer P; Brahimi S
Ann Med Interne (Paris); 1998 Mar; 149(2):94-100. PubMed ID: 11490531
[TBL] [Abstract][Full Text] [Related]
34. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Nand S; Stock W; Godwin J; Fisher SG
Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
[TBL] [Abstract][Full Text] [Related]
35. [Polycythaemia vera--diagnosis and therapy].
Lechner K; Geissler K; Gisslinger H
Wien Klin Wochenschr; 1999 Aug; 111(15):582-9. PubMed ID: 10483672
[TBL] [Abstract][Full Text] [Related]
36. Leukemic transformation of polycythemia vera after treatment with hydroxyurea with abnormalities of chromosome 17.
Tóthová E; Fricová M; Stecová N; Hlebasková M; Kafková A; Raffac S; Guman T; Svorcová E; Nebesnáková E
Neoplasma; 2001; 48(5):389-92. PubMed ID: 11845984
[TBL] [Abstract][Full Text] [Related]
37. Risk stratification, staging, and treatment of patients with polycythemia vera: Italian and European collaboration on low-dose aspirin in polycythemia data.
Finazzi G
Semin Thromb Hemost; 2006 Apr; 32(3):276-82. PubMed ID: 16673282
[TBL] [Abstract][Full Text] [Related]
38. [Association of polycythemia vera and multiple myeloma. Presentation ofa new case and review of the literature].
Prósper F; Paloma MJ; Rifón J; Cuesta B; Hermida J; Rocha E
Sangre (Barc); 1993 Dec; 38(6):497-9. PubMed ID: 8171387
[TBL] [Abstract][Full Text] [Related]
39. Evidence-based management of polycythemia vera.
Barbui T; Finazzi G
Best Pract Res Clin Haematol; 2006; 19(3):483-93. PubMed ID: 16781485
[TBL] [Abstract][Full Text] [Related]
40. Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk.
Barbui T; Finazzi G
Semin Thromb Hemost; 2007 Jun; 33(4):321-9. PubMed ID: 17525889
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
